HRP20211598T1 - Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik - Google Patents
Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik Download PDFInfo
- Publication number
- HRP20211598T1 HRP20211598T1 HRP20211598TT HRP20211598T HRP20211598T1 HR P20211598 T1 HRP20211598 T1 HR P20211598T1 HR P20211598T T HRP20211598T T HR P20211598TT HR P20211598 T HRP20211598 T HR P20211598T HR P20211598 T1 HRP20211598 T1 HR P20211598T1
- Authority
- HR
- Croatia
- Prior art keywords
- divided particles
- finely divided
- use according
- powder formulation
- range
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 17
- 238000009472 formulation Methods 0.000 title claims 13
- 239000000843 powder Substances 0.000 title claims 13
- 230000001078 anti-cholinergic effect Effects 0.000 title 1
- 239000003246 corticosteroid Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002245 particle Substances 0.000 claims 18
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 claims 3
- 229960002462 glycopyrronium bromide Drugs 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 229940125369 inhaled corticosteroids Drugs 0.000 claims 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims 1
- 238000011418 maintenance treatment Methods 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Claims (11)
1. Formulacija praška za inhalaciju za upotrebu inhalacijom u sprječavanju i/ili liječenju upalne i/ili opstruktivne bolesti dišnih puteva, time da spomenuti prašak sadrži sljedeće:
(A) nosač koji sadrži sljedeće:
(a) 80 do 95 posto po masi, zasnovano na ukupnoj masi spomenutog nosača, grubo usitnjenih čestice alfa-laktoza monohidrata koji ima prosječnu veličinu čestica od najmanje 175 µm i maseni promjer u rasponu od 100 do 600 mikrona, te
(b) 19.6 do 4.9 posto po masi, zasnovano na ukupnoj masi spomenutog nosača, fino usitnjenih čestica alfa-laktoza monohidrata te 0.1 do 0.4 posto po masi, zasnovano na ukupnoj masi spomenutog nosača, magnezijeva stearata, te
(B) fino usitnjene čestice glikopironijeva bromida, formoterol-fumarat dihidrata te beklometoazon-dipropionata kao aktivne tvari, a spomenuti postupak obuhvaća sljedeće:
(i) miješanje cijele količine spomenutih grubo usitnjenih čestica alfa-laktoza monohidrata, cijele količine magnezijeva stearata, prvog obroka spomenutih fino usitnjenih čestica fiziološki prihvatljivog ekscipijensa, cijele količine fino usitnjenih čestica glikopironijeva bromida, beklometazon-dipropionata i formoterol-fumarat dihidrata u posudi za mješač s potresivanjem pri brzini rotacije ne manjom od 16 rpm u vremenu ne kraćem od 60 minuta da se dobije prva smjesa, i
(ii) dodavanje zaostalog dijela spomenutih fino usitnjenih čestica fiziološki prihvatljivog ekscipijensa u spomenutu prvu smjesu, za dobivanje druge smjese te miješanje spomenute druge smjese pri brzini rotacije ne nižoj od 16 rpm u vremenu od najmanje 120 minuta,
pri čemu je udio spomenutog prvog obroka spomenutih fino usitnjenih čestica alfa-laktoza monohidrata u rasponu od 40% i 60% zasnovano na ukupnoj masi svih spomenutih fino usitnjenih čestica alfa-laktoza monohidrata te pri čemu je udio ekstrafino usitnjenih čestica svakog aktivnog sastojka između 20 i 35%.
2. Formulacija praška za inhalaciju prema patentnom zahtjevu 1, naznačena time da je upalna i/ili opstruktivna bolest dišnih puteva odabrana iz grupe koja se sastoji od kronične opstruktivne bolesti pluća (COPD), astme i kroničnog opstruktivnog bronhitisa.
3. Formulacija praška za upotrebu prema patentnom zahtjevu 1 ili 2, naznačena time da je bolest odabrana od ozbiljne i/ili vrlo ozbiljne opstruktivne bolesti pluća (COPD).
4. Formulacija praška za upotrebu prema patentnim zahtjevima 1 do 3, naznačena time da je za održavanje liječenja pacijenata s COPD čiji su simptomi ograničen protok zraka i povijest pogoršanja.
5. Formulacija praška za upotrebu prema patentnom zahtjevu 1 ili 2, naznačena time da bolest jest perzistetna astma ili astma koja nije kontrolirana srednjim ili visokim dozama inhaliranih kortikosteroida u kombinaciji s dugo djelujućim beta-2-agonistima.
6. Formulacija praška za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da spomenuti postupak nadalje obuhvaća: (iii) daljnje miješanje formulacije dobivene u (ii) da se postigne homogena raspodjela spomenutih aktivnih sastojaka.
7. Formulacija praška za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da je udio spomenutog prvog obroka spomenutih fino usitnjenih čestica alfa-laktoza monohidrata u rasponu od 45% i 55%.
8. Formulacija praška za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da je udio ekstrafiniho usitnjenih čestica beklometazon-dipropionata i formoterol-fumarat dihidrata u rasponu između 20 i 35% te da je udio ekstrafino usitnjenih čestica glikopironijeva bromida u rasponu od 20 i 30%.
9. Formulacija praška za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da grubo usitnjene čestice imaju maseni promjer u rasponu od 200 i 400 mikrona.
10. Formulacija praška za upotrebu prema patentnom zahtjevu 9, naznačena time da grubo usitnjene čestice imaju maseni promjer u rasponu od 210 i 360 mikrona.
11. Formulacija praška za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da je omjer odjela grubo usitnjenih čestica a), finu usitnjenih čestica alfa-laktoza monohidrata i magnezijeva stearata u rasponu od 85:14.7:0.3 i 90:9.8:0.2 po masi.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15194660 | 2015-11-16 | ||
| EP19205980.6A EP3620176B1 (en) | 2015-11-16 | 2016-11-14 | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211598T1 true HRP20211598T1 (hr) | 2022-01-07 |
Family
ID=54548062
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211600TT HRP20211600T1 (hr) | 2015-11-16 | 2016-11-14 | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik |
| HRP20211598TT HRP20211598T1 (hr) | 2015-11-16 | 2016-11-14 | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik |
| HRP20200537TT HRP20200537T1 (hr) | 2015-11-16 | 2020-04-01 | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211600TT HRP20211600T1 (hr) | 2015-11-16 | 2016-11-14 | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200537TT HRP20200537T1 (hr) | 2015-11-16 | 2020-04-01 | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US10086004B2 (hr) |
| EP (3) | EP3620176B1 (hr) |
| JP (1) | JP6963548B2 (hr) |
| KR (1) | KR20180082443A (hr) |
| CN (1) | CN108289962B (hr) |
| AR (1) | AR106688A1 (hr) |
| AU (1) | AU2016356858B2 (hr) |
| CA (1) | CA3005290A1 (hr) |
| CL (1) | CL2018001298A1 (hr) |
| CO (1) | CO2018005141A2 (hr) |
| CY (3) | CY1123042T1 (hr) |
| DK (3) | DK3628331T3 (hr) |
| EA (1) | EA037716B1 (hr) |
| ES (3) | ES2895687T3 (hr) |
| GE (1) | GEP20207157B (hr) |
| HR (3) | HRP20211600T1 (hr) |
| HU (3) | HUE049751T2 (hr) |
| IL (1) | IL259329B (hr) |
| LT (3) | LT3628331T (hr) |
| MA (3) | MA50487B1 (hr) |
| MD (3) | MD3620176T2 (hr) |
| ME (1) | ME03778B (hr) |
| MX (1) | MX2018005977A (hr) |
| MY (1) | MY186229A (hr) |
| PE (1) | PE20181488A1 (hr) |
| PH (1) | PH12018501022B1 (hr) |
| PL (3) | PL3377108T3 (hr) |
| PT (3) | PT3377108T (hr) |
| RS (3) | RS62404B1 (hr) |
| SA (1) | SA518391570B1 (hr) |
| SG (2) | SG10201912093YA (hr) |
| SI (3) | SI3620176T1 (hr) |
| TW (1) | TWI731891B (hr) |
| UA (1) | UA125019C2 (hr) |
| WO (1) | WO2017085004A1 (hr) |
| ZA (1) | ZA201803168B (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018206619A1 (en) * | 2017-05-11 | 2018-11-15 | Chiesi Farmaceutici S.P.A. | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
| RU2742376C1 (ru) * | 2017-05-11 | 2021-02-05 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик |
| US11433063B1 (en) | 2019-03-12 | 2022-09-06 | Belhaven Biopharma, Inc. | Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides |
| BR112021019077A2 (pt) * | 2019-03-27 | 2021-11-30 | Kemin Ind Inc | Métodos para fabricar um ou mais carboxilatos de metal e múltiplos carboxilatos de metal em uma única reação, e, carboxilato de metal |
| CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| WO2021143785A1 (zh) * | 2020-01-15 | 2021-07-22 | 四川海思科制药有限公司 | 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法 |
| WO2022045995A1 (en) * | 2020-08-28 | 2022-03-03 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | A process for the preparation of dry powder compositions for inhalation |
| US20220304894A1 (en) * | 2021-03-24 | 2022-09-29 | Cmpd Licensing, Llc | Drug powderization within vials |
| WO2023117967A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| SI1386630T1 (sl) | 2002-07-31 | 2006-10-31 | Chiesi Farma Spa | Inhalator za prasek |
| EP2515855B3 (en) | 2009-12-23 | 2023-05-03 | Chiesi Farmaceutici S.p.A. | Combination therapy for COPD |
| ES2663878T3 (es) * | 2012-12-06 | 2018-04-17 | Chiesi Farmaceutici S.P.A. | Compuestos que tienen actividad antagonista del receptor muscarínico y actividad agonista del receptor beta-2 adrenérgico |
| JP6421989B2 (ja) * | 2012-12-06 | 2018-11-14 | チエシ ファルマスティスィ エス．ピー．エー． | ムスカリン受容体アンタゴニストおよびβ２アドレナリン受容体アゴニスト活性を有する化合物 |
| US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| SI3019153T1 (sl) * | 2013-07-11 | 2018-12-31 | Chiesi Farmaceutici S.P.A. | Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo |
-
2016
- 2016-11-14 HU HUE16801982A patent/HUE049751T2/hu unknown
- 2016-11-14 ES ES19205936T patent/ES2895687T3/es active Active
- 2016-11-14 SI SI201631331T patent/SI3620176T1/sl unknown
- 2016-11-14 EP EP19205980.6A patent/EP3620176B1/en active Active
- 2016-11-14 GE GEAP201614783A patent/GEP20207157B/en unknown
- 2016-11-14 PT PT168019826T patent/PT3377108T/pt unknown
- 2016-11-14 MA MA50487A patent/MA50487B1/fr unknown
- 2016-11-14 MA MA50488A patent/MA50488B1/fr unknown
- 2016-11-14 EP EP16801982.6A patent/EP3377108B1/en active Active
- 2016-11-14 UA UAA201805271A patent/UA125019C2/uk unknown
- 2016-11-14 TW TW105137048A patent/TWI731891B/zh active
- 2016-11-14 MY MYPI2018000704A patent/MY186229A/en unknown
- 2016-11-14 SI SI201631349T patent/SI3628331T1/sl unknown
- 2016-11-14 DK DK19205936.8T patent/DK3628331T3/da active
- 2016-11-14 MD MDE20200899T patent/MD3620176T2/ro unknown
- 2016-11-14 CA CA3005290A patent/CA3005290A1/en active Pending
- 2016-11-14 RS RS20211196A patent/RS62404B1/sr unknown
- 2016-11-14 SI SI201630682T patent/SI3377108T1/sl unknown
- 2016-11-14 RS RS20211283A patent/RS62506B1/sr unknown
- 2016-11-14 MD MDE20180917T patent/MD3377108T2/ro unknown
- 2016-11-14 HR HRP20211600TT patent/HRP20211600T1/hr unknown
- 2016-11-14 MD MDE20200898T patent/MD3628331T2/ro unknown
- 2016-11-14 LT LTEP19205936.8T patent/LT3628331T/lt unknown
- 2016-11-14 JP JP2018524832A patent/JP6963548B2/ja active Active
- 2016-11-14 LT LTEP16801982.6T patent/LT3377108T/lt unknown
- 2016-11-14 PL PL16801982T patent/PL3377108T3/pl unknown
- 2016-11-14 SG SG10201912093YA patent/SG10201912093YA/en unknown
- 2016-11-14 LT LTEP19205980.6T patent/LT3620176T/lt unknown
- 2016-11-14 KR KR1020187013286A patent/KR20180082443A/ko unknown
- 2016-11-14 HU HUE19205936A patent/HUE056260T2/hu unknown
- 2016-11-14 DK DK19205980.6T patent/DK3620176T3/da active
- 2016-11-14 ES ES16801982T patent/ES2783855T3/es active Active
- 2016-11-14 CN CN201680066801.5A patent/CN108289962B/zh active Active
- 2016-11-14 PT PT192059806T patent/PT3620176T/pt unknown
- 2016-11-14 SG SG11201804050QA patent/SG11201804050QA/en unknown
- 2016-11-14 MX MX2018005977A patent/MX2018005977A/es unknown
- 2016-11-14 RS RS20200440A patent/RS60171B1/sr unknown
- 2016-11-14 EA EA201890966A patent/EA037716B1/ru unknown
- 2016-11-14 DK DK16801982.6T patent/DK3377108T3/da active
- 2016-11-14 PT PT192059368T patent/PT3628331T/pt unknown
- 2016-11-14 HR HRP20211598TT patent/HRP20211598T1/hr unknown
- 2016-11-14 ME MEP-2020-80A patent/ME03778B/me unknown
- 2016-11-14 AR ARP160103473A patent/AR106688A1/es unknown
- 2016-11-14 PE PE2018000973A patent/PE20181488A1/es unknown
- 2016-11-14 HU HUE19205980A patent/HUE056441T2/hu unknown
- 2016-11-14 ES ES19205980T patent/ES2891073T3/es active Active
- 2016-11-14 PL PL19205980T patent/PL3620176T3/pl unknown
- 2016-11-14 AU AU2016356858A patent/AU2016356858B2/en active Active
- 2016-11-14 PL PL19205936T patent/PL3628331T3/pl unknown
- 2016-11-14 MA MA43256A patent/MA43256B1/fr unknown
- 2016-11-14 WO PCT/EP2016/077558 patent/WO2017085004A1/en active Application Filing
- 2016-11-14 EP EP19205936.8A patent/EP3628331B1/en active Active
- 2016-11-15 US US15/351,562 patent/US10086004B2/en active Active
-
2018
- 2018-05-14 SA SA518391570A patent/SA518391570B1/ar unknown
- 2018-05-14 ZA ZA2018/03168A patent/ZA201803168B/en unknown
- 2018-05-14 IL IL259329A patent/IL259329B/en active IP Right Grant
- 2018-05-14 CL CL2018001298A patent/CL2018001298A1/es unknown
- 2018-05-15 PH PH12018501022A patent/PH12018501022B1/en unknown
- 2018-05-16 CO CONC2018/0005141A patent/CO2018005141A2/es unknown
- 2018-08-27 US US16/113,026 patent/US10772896B2/en active Active
-
2020
- 2020-04-01 HR HRP20200537TT patent/HRP20200537T1/hr unknown
- 2020-04-06 CY CY20201100319T patent/CY1123042T1/el unknown
- 2020-08-07 US US16/987,695 patent/US10966991B2/en active Active
-
2021
- 2021-02-24 US US17/184,181 patent/US11628175B2/en active Active
- 2021-09-07 CY CY20211100793T patent/CY1124475T1/el unknown
- 2021-09-09 CY CY20211100797T patent/CY1124490T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211598T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| HRP20210704T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| HRP20211599T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| HRP20221432T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| HRP20191686T1 (hr) | Mikronizirane čestice aktivnih tvari za praškaste formulacije za inhalaciju u niskim dozama | |
| RU2012145762A (ru) | Способ получения частиц с пониженным электростатическим зарядом | |
| JP2013542940A5 (hr) | ||
| JP2019501876A5 (hr) | ||
| JP2018537453A5 (hr) | ||
| HRP20151214T1 (hr) | Pripravak za inhalaciju koji sadrži aklidinij za lijeäśenje kroniäśne opstruktivne pluä†ne bolesti | |
| RU2014140539A (ru) | Агрегированные частицы | |
| JP2015519356A5 (hr) | ||
| HRP20200618T1 (hr) | Metoda za pripremu inhalacijskih pripravaka suhog praha | |
| CN104644618A (zh) | 一种干粉吸入剂及其制备方法 | |
| HRP20140818T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| EP2821061B1 (en) | Novel inhalation formulations | |
| US20150150802A1 (en) | Dry powder inhaler compositions comprising long acting muscarinic antagonists | |
| EA201591871A1 (ru) | Фармацевтическая композиция, содержащая будесонид и формотерол | |
| RU2504382C1 (ru) | Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения | |
| RU2522213C2 (ru) | Фармацевтический ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких, содержащих в качестве активного вещества микронизированный тиотропия бромид, и способ его получения | |
| WO2015065222A1 (ru) | Фармацевтический ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких, содержащий в качестве активного вещества микронизированный тиотропия бромид, и способ его получения | |
| MX2017004583A (es) | Composicion farmaceutica que contiene budesonida y formoterol. | |
| WO2015065220A1 (ru) | Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения |